Navigation Links
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Date:10/2/2009

The Company is also today announcing a change to its financial guidance for 2009. Based on its current projections of net operating expense, the Company now expects to end 2009 with approximately $70-$80 million in cash.

Conference Call and Webcast

Amicus will host a conference call to discuss the Plicera Phase 2 preliminary results, today, October 2, 2009, at 5 p.m. EDT. Interested participants and investors may access the conference call by dialing 888-263-2958. A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT. Access numbers for this replay are 888-203-1112; participant code 4377067.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com.

About Gaucher Disease

Gaucher disease is a lysosomal storage disorder caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets, and skeletal complications. In some cases there is significant impairment of the central nervous system.

Gaucher
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
2. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... 2015 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... federal multidistrict litigation underway in U.S. District Court, ... the parties involved in the proceeding submitted a ... other things, preparation for the litigation’s upcoming bellwether ... plaintiffs and defendants have conducted depositions of non-party ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... transplants after removing small cancerous and benign masses from ... December issue of the urology journal BJUI. The ... of Maryland School of Medicine in Baltimore, could offer ... as well as increasing the supply of viable organs. ...
... Nutra Pharma ... the Food and Drug Administration (FDA). This registration is considered the final step required by ... the treatment of chronic pain. , ... Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology ...
... ... Changes in Industry Standards and Compliance Requirements , ... (PRWEB) December 7, 2009 -- BridgeGate ... the launch of its new integration technology training program, which will kick off ...
... in comparison study , SUNDAY, Dec. 6 (HealthDay ... therapy for prostate cancer are best controlled by ... according to a new study. , Androgen suppression ... prostate cancer, but about 80 percent of patients ...
... older anti-clotting drug, with fewer hassles, study finds , MONDAY, ... dabigatran etexilate may be just as effective in preventing dangerous ... for doctors and patients to manage, a new study finds. ... in Europe; it is not yet approved for use in ...
... ... offer top-of-the-line implementation services to Talyst’s clients in the acute care industry. ... (PRWEB) ... of the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a ...
Cached Medicine News:Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
(Date:4/24/2015)... , April 24, 2015 Today, humanity takes a ... the singularity, and fat-free cronuts: 1-800 CONTACTS announces their new ... in just two taps. Two taps. New contacts. ... The app also features LensGauge which helps keep ... when you need to reorder. "Since our inception, ...
(Date:4/24/2015)... April 24, 2015  A new study shows an "alarming ... drugs used to slow the progression of multiple sclerosis or ... by researchers at Oregon Health & Science University (OHSU) and ... the number of MS drugs in the marketplace over the ... stabilized costs for patients who use those drugs. Researchers found ...
(Date:4/24/2015)... S.C. , April 24, 2015  Span-America ... plans to release its fiscal 2015 second quarter ... regular trading. The company will conduct ... Friday, May 1, to review the company,s financial and ... 2015.  A live broadcast of the conference call ...
Breaking Medicine Technology:Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4
... influenza,transmission patterns in the Southern Hemisphere and ... finding that,each season influenza travels from low ... populated centers. Their work, funded by the,Fogarty ... Institutes,of Health (NIH), can improve planning for ...
... - An overexpressed protein,protects human pancreatic cancer ... of the body's natural defenses against,out-of-control cell growth, ... Cancer Center report in the March issue of ... by the abbreviation,TG2, previously has been found by ...
Cached Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
Half Eye Trial Frame - Child...
Sickle blade. Flat stock myringotomy blade....
BD Beaver Phaco slit blade, 3.2 mm, angled 45, bevel up. matte finish offers a precise incision which minimizes leakage during phaco procedures. Precise incision minimizes leakage during phaco proced...
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
Medicine Products: